In its release the DEA seems to acknowledge cannabis’s medical potential while at the same time reminding us that it remains more tightly regulated than opium or cocaine: “Marijuana is a Schedule I controlled substance because of the feel hemp cbd oil tincture after vaping cannabidiol presence of tetrahydrocannabinol (THC) marijuana’s psychoactive ingredient. Because CBD contains less than 1 percent THC and has shown some potential medicinal value there is great interest in studying it for medical applications. Currently CBD is a Schedule I controlled substance as defined under the CSA.
MEDLINE e18. Rick Simpson Oil Denver Co chang AE Shiling DJ Stillman RC et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-51. MEDLINE e19. Colls BM Ferry DG Gray AJ Harvey VJ McQueen EG: The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 1980; 91: 449-51. MEDLINE e20.
CrossRef MEDLINE 22. Engels FK de Jong FA Sparreboom A et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007; 12: 291-300. CrossRef MEDLINE 23. Hollister LE: Interactions of marihuana and 9-THC with other drugs. In: Nahas G Sutin KM Harvey DJ Agurell S (eds.): Marihuana and Medicine:
- Novotna A Mares J Ratcliffe S et al
- Wien Klin Wochenschr 2006; 118: 327-35 MEDLINE e97
- CrossRef 9
- J Clin Pharmacol 1981; 21(8-9 Suppl): 64-9
- Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain
. Totowa NJ: Humana Press 1999: 273-7.
Vaney C Heinzel-Gutenbrunner M Jobin P et al.: Efficacy safety and tolerability of an Rick Simpson Oil Denver Co orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized double-blind placebo-controlled crossover study. Multiple Sclerosis 2004; 10: 417-24. MEDLINE e8.
Müller-Vahl KR Schneider U Prevedel H et al.: ?9-tetrahydrocannabinol (THC) is Rick Simpson Oil Denver Co effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459-65. MEDLINE e110. Sieradzan KA Fox SH Dick J Brotchie JM: The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD). Movement Disorders 1998; 13(Suppl 2): 29.
MEDLINE PubMed Central e37. Chan HS Correia JA MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind crossover trial. Pediatrics 1987; 79: 946-52.
Ungerleider JT Sarna G Fairbanks LA Goodnight J Andrysiak T Jamison K: THC or compazine for the cancer chemotherapy patient – the UCLA study. Part II: patient drug preference. Am J Clin Oncol 1985; 8: 142-7. Rick Simpson Oil Denver Co MEDLINE e34. Meiri E Jhangiani H Vredenburgh JJ et al.: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-43.
Citron ML Herman TS Vreeland F Krasnow SH Fossieck BE Jr: Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109-12. MEDLINE e54. Higi M Niederle N Bremer K Schmitt G Schmidt CG Seeber S: Levonantradol bei der Behandlung von zytostatika-bedingter Übelkeit und Erbrechen.
Wada JK Bogdon DL Gunnell JC Hum GJ Gota CH Rieth TE: Double-blind randomized crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Rev 1982; 9(Suppl B): 39-44. MEDLINE e53.
Stambaugh Jr JE McAdams J Vreeland F: Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Int J Clin Pharmacol Res 1984; 24: 480-5. MEDLINE e57. American Society of Clinical Oncology Kris MG Hesketh PJ et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-47.
Rintala DH Fiess RN Tan G Holmes SA Bruel BM: Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. cannabinoid function in learning memory and plasticity Am J Phys Med Rehabil 2010; 89: 840-8. CrossRef MEDLINE e73.
Beal JE Olson R Laubenstein L et al.: Dronabinol as a Rick Simpson Oil Denver Co treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag 1995; 10: 89-97. MEDLINE e61.
MEDLINE e110. Sieradzan KA Fox SH Dick J Brotchie JM: The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD). Movement Disorders 1998; 13(Suppl 2): 29. e111.
A printable copy of these instructions is also included in the links at the bottom. You will need to have your medical history/records mailed with the cover letter checklist and referral letter from your primary treating neurologist. The medical records should include at the very least the following information: Report of most recent Brain MRI (Include date of MRI report) Report of most recent Electrocardiogram (ECG) (Include date of ECG report) Digital copy of a routine EEG along with the formal written report performed within 3 months prior to submitting these records for CBD Treatment Approval Committee review Documentation of failed AEDs including one trial of a combination of two concomitant AEDs without successful seizure control. Documentation of between 1-4 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to submitting these records for CBD Treatment Approval Committee review. Current Medication List If applicable documentation of VNS or RNS implantation and evidence that settings have not been adjusted within 3 months prior to submitting these records for CBD Treatment Approval Committee review If applicable provide report of Corpus Callostomy or other prior epilepsy surgery (Include the date of the surgery). If on ketogenic diet documentation that you have been on stable ratio for a minimum of 3 months. Documentation indicating seizure type(s) and number of seizures of each type per month Documentation of seizure calendar for at least 3 months prior to submitting these records for CBD Treatment Approval Committee review; the patient will need to provide an updated calendar at the time of enrollment.